Fred Witjes

2.3k total citations
29 papers, 1.6k citations indexed

About

Fred Witjes is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Fred Witjes has authored 29 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Surgery, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Fred Witjes's work include Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (13 papers) and Cancer Treatment and Pharmacology (4 papers). Fred Witjes is often cited by papers focused on Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (13 papers) and Cancer Treatment and Pharmacology (4 papers). Fred Witjes collaborates with scholars based in Netherlands, United States and Italy. Fred Witjes's co-authors include Stans Verhagen, Marieke Gielissen, Gijs Bleijenberg, Michele Spina, Christine de Balincourt, A.T. van Oosterom, Cora N. Sternberg, Sophie D. Fosså, P.H.M. de Mulder and Christine Théodore and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Fred Witjes

28 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fred Witjes Netherlands 11 1.1k 503 389 211 182 29 1.6k
Frédéric D. Birkhäuser Switzerland 20 970 0.9× 219 0.4× 463 1.2× 334 1.6× 99 0.5× 40 1.5k
Vignesh T. Packiam United States 24 1.1k 1.0× 326 0.6× 356 0.9× 410 1.9× 130 0.7× 126 1.6k
W. Oosterlinck Belgium 19 1.3k 1.2× 280 0.6× 353 0.9× 862 4.1× 278 1.5× 79 2.0k
C. van de Beek Netherlands 15 1.0k 0.9× 195 0.4× 720 1.9× 499 2.4× 177 1.0× 28 1.9k
Dov Engelstein Israel 17 356 0.3× 249 0.5× 332 0.9× 212 1.0× 97 0.5× 37 1.1k
Filippo Pederzoli Italy 25 532 0.5× 183 0.4× 177 0.5× 231 1.1× 124 0.7× 85 1.5k
Sanjay G. Patel United States 19 800 0.7× 211 0.4× 538 1.4× 418 2.0× 187 1.0× 43 1.5k
Massimo Iafrate Italy 17 465 0.4× 269 0.5× 440 1.1× 305 1.4× 70 0.4× 69 1.3k
Marc‐Olivier Timsit France 20 475 0.4× 242 0.5× 552 1.4× 121 0.6× 111 0.6× 105 1.3k
Roberto Casella Switzerland 21 619 0.6× 162 0.3× 448 1.2× 215 1.0× 85 0.5× 50 1.2k

Countries citing papers authored by Fred Witjes

Since Specialization
Citations

This map shows the geographic impact of Fred Witjes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Witjes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Witjes more than expected).

Fields of papers citing papers by Fred Witjes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Witjes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Witjes. The network helps show where Fred Witjes may publish in the future.

Co-authorship network of co-authors of Fred Witjes

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Witjes. A scholar is included among the top collaborators of Fred Witjes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Witjes. Fred Witjes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Galsky, Matt D., Andrea Necchi, Neal D. Shore, et al.. (2020). Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905.. Journal of Clinical Oncology. 38(6_suppl). TPS593–TPS593. 2 indexed citations
3.
4.
Bajorin, Dean F., Matthew D. Galsky, Jürgen E. Gschwend, et al.. (2017). A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274). Annals of Oncology. 28. v327–v327. 6 indexed citations
5.
Witjes, Fred, et al.. (2017). 68Ga–Prostate-Specific Membrane Antigen Uptake in Gastrointestinal Stromal Tumor. Clinical Nuclear Medicine. 43(1). 60–61. 8 indexed citations
6.
Friedman, Boris, Yoram Dekel, Andrea Tubaro, et al.. (2016). PD11-05 THE CHEMOABLATIVE EFFECT OF VESIGEL INSTILLATION IN PATIENTS WITH NMIBC – PRELIMINARY RESULTS. The Journal of Urology. 195(4S). 5 indexed citations
7.
Colombo, Renzo, et al.. (2016). Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. International Journal of Hyperthermia. 32(4). 351–362. 26 indexed citations
8.
Colombel, Marc, Axel Heidenreich, Luis Martínez‐Piñeiro, et al.. (2013). Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: Overview and the Unmet Clinical Need for Alternative Adjuvant Therapy as Studied in the MAGNOLIA Trial. European Urology. 65(3). 509–511. 11 indexed citations
9.
Ploeg, Martine, Katja K.H. Aben, Emile N. van Lin, et al.. (2011). Prognostic Factors for Survival in Patients With Recurrence of Muscle Invasive Bladder Cancer After Treatment With Curative Intent. Clinical Genitourinary Cancer. 9(1). 14–21. 10 indexed citations
10.
Gontero, Paolo, Andreas Böhle, Per‐Uno Malmström, et al.. (2009). The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer. European Urology. 57(3). 410–429. 142 indexed citations
11.
Oosterlinck, Willem, Fred Witjes, & Richard Sylvester. (2008). Diagnostic and Prognostic Factors in Non-Muscle-Invasive Bladder Cancer and Their Influence on Treatment and Outcomes. European Urology Supplements. 7(7). 516–523. 1 indexed citations
12.
Sternberg, C., Daniel P. Petrylak, Fred Witjes, et al.. (2007). Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Journal of Clinical Oncology. 25(18_suppl). 5019–5019. 47 indexed citations
13.
Gielissen, Marieke, Stans Verhagen, Fred Witjes, & Gijs Bleijenberg. (2006). Effects of Cognitive Behavior Therapy in Severely Fatigued Disease-Free Cancer Patients Compared With Patients Waiting for Cognitive Behavior Therapy: A Randomized Controlled Trial. Journal of Clinical Oncology. 24(30). 4882–4887. 246 indexed citations
14.
Sternberg, C., P.H.M. de Mulder, Jan H. Schornagel, et al.. (2005). Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. Journal of Clinical Oncology. 23(16_suppl). 4528–4528. 6 indexed citations
15.
Nathan, Faith E., C. Sternberg, Oliver Sartor, et al.. (2005). Satraplatin: A new treatment option for patients with hormone refractory prostate cancer. Journal of Clinical Oncology. 23(16_suppl). 4802–4802. 4 indexed citations
16.
Jocham, D., Fred Witjes, Sigrid Wagner, et al.. (2005). IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDY. The Journal of Urology. 174(3). 862–866. 230 indexed citations
17.
Durek, Christoph, Sigrid Wagner, Jeroen van Moorselaar, et al.. (2004). 369 The significance of hexyl 5-aminolevulinate hydrochloride based fluorescence cystoscopy in treatment decisions — results of a prospective phase 3 multicenter study. European Urology Supplements. 3(2). 95–95. 8 indexed citations
18.
19.
Boer, Elizabeth C. de, Wim H. de Jong, A.P.M. van der Meijden, et al.. (1991). Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. Urological Research. 19(1). 45–50. 85 indexed citations
20.
Witjes, Fred, et al.. (1989). Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Urology. 33(5). 411–415. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frédéric D. Birkhäuser Breakdown of academic impact, for papers by Vignesh T. Packiam Breakdown of academic impact, for papers by W. Oosterlinck Breakdown of academic impact, for papers by C. van de Beek Breakdown of academic impact, for papers by Dov Engelstein Breakdown of academic impact, for papers by Filippo Pederzoli Breakdown of academic impact, for papers by Sanjay G. Patel Breakdown of academic impact, for papers by Massimo Iafrate Breakdown of academic impact, for papers by Marc‐Olivier Timsit Breakdown of academic impact, for papers by Roberto Casella
Rankless by CCL
2026